← Russell 3000 cross-section

IKT Inhibikase Therapeutics, Inc.

Trailing twelve months to 2025-09-30 · as filed 2025-11-14, not restated
Healthcare

Scale

Market cap
$347m
Revenue TTM
$0m
Net income TTM
$-48m
Free cash flow
$-26m
Composite score
Sector rank
#2591

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
-7.39%
Earnings yield vs 10-yr
-18.49pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
-65.4%
ROIC
-151.1%
Revenue growth
-100.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Wainwright & Co., LLC, as sales agent, which was subsequently terminated in December 2024. Prior to our initial public offering, we financed our operations primarily through revenue generated by private, state and federal grants and contracts and subsequently through the issuance of securities in various offerings. The One Big Beautiful Bill Act (the “OBBBA”) was signed into law on July 4, 2025 and made significant changes to the treatment of research and development (“R&D”) expenditures under Section 174 of the United States Internal Revenue Code of 1986, as amended (“Code”).Inhibikase Therapeutics, Inc., 10-K, period ended 2025-12-31, filed 2026-03-26

Read the full passage →